Cargando…
Different therapeutic approaches on quality of life in patients with inflammatory bowel disease
BACKGROUND: The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the im...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271410/ https://www.ncbi.nlm.nih.gov/pubmed/25421821 http://dx.doi.org/10.1186/s12876-014-0199-5 |
_version_ | 1782349600567328768 |
---|---|
author | Xu, Junjie Lin, Hui Feng, Xu Tang, Minyue Shen, Jun Ran, Zhihua |
author_facet | Xu, Junjie Lin, Hui Feng, Xu Tang, Minyue Shen, Jun Ran, Zhihua |
author_sort | Xu, Junjie |
collection | PubMed |
description | BACKGROUND: The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated. METHODS: Consecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment. RESULTS: MCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048). CONCLUSIONS: MCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-014-0199-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4271410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42714102014-12-20 Different therapeutic approaches on quality of life in patients with inflammatory bowel disease Xu, Junjie Lin, Hui Feng, Xu Tang, Minyue Shen, Jun Ran, Zhihua BMC Gastroenterol Research Article BACKGROUND: The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated. METHODS: Consecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment. RESULTS: MCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048). CONCLUSIONS: MCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-014-0199-5) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-25 /pmc/articles/PMC4271410/ /pubmed/25421821 http://dx.doi.org/10.1186/s12876-014-0199-5 Text en © Xu et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Xu, Junjie Lin, Hui Feng, Xu Tang, Minyue Shen, Jun Ran, Zhihua Different therapeutic approaches on quality of life in patients with inflammatory bowel disease |
title | Different therapeutic approaches on quality of life in patients with inflammatory bowel disease |
title_full | Different therapeutic approaches on quality of life in patients with inflammatory bowel disease |
title_fullStr | Different therapeutic approaches on quality of life in patients with inflammatory bowel disease |
title_full_unstemmed | Different therapeutic approaches on quality of life in patients with inflammatory bowel disease |
title_short | Different therapeutic approaches on quality of life in patients with inflammatory bowel disease |
title_sort | different therapeutic approaches on quality of life in patients with inflammatory bowel disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271410/ https://www.ncbi.nlm.nih.gov/pubmed/25421821 http://dx.doi.org/10.1186/s12876-014-0199-5 |
work_keys_str_mv | AT xujunjie differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease AT linhui differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease AT fengxu differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease AT tangminyue differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease AT shenjun differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease AT ranzhihua differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease |